Justin R. Fallon,Michael Rafii,Mark A. Bowe,Beth A. McKechnie,Alison R. Amenta,Mary Lynn Mercado,Hiroki Hagiwara
申请号:
US14473834
公开号:
US20150182589A1
申请日:
2014.08.29
申请国别(地区):
US
年份:
2015
代理人:
摘要:
The invention provides, among other aspects, compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; diseases or conditions associated with an abnormal level or activity of collagen VI; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); and disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation.